Invesco NASDAQ Biotechnology ETF
IBBQ
9 hedge funds and large institutions have $8.59M invested in Invesco NASDAQ Biotechnology ETF in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
13.92% more ownership
Funds ownership: 40.42% → 54.33% (+14%)
18% less funds holding
Funds holding: 11 → 9 (-2)
20% less capital invested
Capital invested by funds: $10.7M → $8.59M (-$2.08M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBP
Banco BTG Pactual
Rio De Janeiro,
Brazil
|
+$744K |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$278K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$193K |
| 4 |
CIAS
Capital Investment Advisory Services
Raleigh,
North Carolina
|
+$24.8K |
| 5 |
CAL
Capital Analysts LLC
Fort Washington,
Pennsylvania
|
+$22.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.94M |
| 2 |
AF
Apexium Financial
Dallas,
Texas
|
-$410K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$62.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$20.7K |
| 5 |
AIP
Ahrens Investment Partners
Lafayette,
Louisiana
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Mirae Asset Global Investments
Seoul,
South Korea
| $6.18M | +$278K | +14,600 | +5% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $811K | -$62.7K | -3,289 | -7% |
|
|
BBP
3
Banco BTG Pactual
Rio De Janeiro,
Brazil
| $734K | +$744K | +39,015 | New |
|
|
CGL
4
Clarius Group LLC
Seattle,
Washington
| $353K | – | – | – |
|
|
5
Bank of America
Charlotte,
North Carolina
| $268K | +$193K | +10,132 | +247% |
|
|
CIAS
6
Capital Investment Advisory Services
Raleigh,
North Carolina
| $201K | +$24.8K | +1,300 | +14% |
|
|
CAL
7
Capital Analysts LLC
Fort Washington,
Pennsylvania
| $23K | +$22.9K | +1,200 | New |
|
8
Morgan Stanley
New York
| $20K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $3K | -$20.7K | -1,084 | -86% |
|
|
10
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.94M | -92,687 | Closed |
|
|
AF
11
Apexium Financial
Dallas,
Texas
| – | -$410K | -17,299 | Closed |
|
|
AIP
12
Ahrens Investment Partners
Lafayette,
Louisiana
| – | -$8K | -400 | Closed |
|
|
FDCDDQ
13
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$6.28K | -300 | Closed |
|
IBBQ Hedge Fund Activity: Q2 2022 in Review
9 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Invesco NASDAQ Biotechnology ETF (IBBQ) for Q2 2022, worth a combined $8.59M — down 20% from $10.7M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IBBQ and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Banco BTG Pactual, opening a new position worth an estimated $744K. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $1.94M sold.
- 9 institutional investors held Invesco NASDAQ Biotechnology ETF (IBBQ) as of Q2 2022, down from 11 in Q1 2022.
- Funds reported $8.59M of Invesco NASDAQ Biotechnology ETF stock for Q2 2022, down 20% quarter-over-quarter.
- 2 funds opened new Invesco NASDAQ Biotechnology ETF positions in Q2 2022 and 4 closed out, a net change of -2 holders.
- The largest Invesco NASDAQ Biotechnology ETF buyer in Q2 2022 was Banco BTG Pactual, an estimated $744K added.
- The largest Invesco NASDAQ Biotechnology ETF seller in Q2 2022 was Royal Bank of Canada, an estimated $1.94M sold.
Based on aggregated 13F filings for Q2 2022.